An observational study in Tenosynovial Giant Cell Tumor, sponsored by Deciphera Pharmaceuticals, LLC. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Giant Cell Tumor of Tendon Sheath with a site in United States — 2 open to participants now, 5 under way, 2 of them phase 3. Giant Cell Tumor of Tendon Sheath · United States.
Among the 16 studies in Giant Cell Tumor of Tendon Sheath with a site in United States, this one is the only one that started in 2025, is one of 2 observational ones, and was the 16th registered.
22 studies on the registry are indexed under Giant Cell Tumor of Tendon Sheath; 5 are open to participants now.
Browse Giant Cell Tumor of Tendon Sheath studies →2 of the 16 studies in Giant Cell Tumor of Tendon Sheath with a site in United States are open now. Recruiting first, the newest first:
Abbisko Therapeutics Co, Ltd · Sites in United States, China
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Giant Cell Tumor of Tendon Sheath studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 3 · Phase 4 1
First in 2010; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 48 across the 14 interventional studies, 50 across the 2 observational. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 8 most frequent:
This study is registered under Deciphera Pharmaceuticals, LLC, one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Deciphera Pharmaceuticals, LLC is the lead sponsor of 24 studies on the registry; 5 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
Ono Pharmaceutical Co. Ltd has 4 studies filed under Giant Cell Tumor of Tendon Sheath — fewer than ten, so there is no comparison to draw.
1 of the studies in Giant Cell Tumor of Tendon Sheath with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07075471Deciphera Pharmaceuticals, LLCMOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Giant Cell Tumor of Tendon Sheath with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.
This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.
Participants being treated for TGCT with vimseltinib in the community setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Participant is active in an interventional clinical trial of vimseltinib
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Duration of Vimseltinib Treatment
Time frame: Baseline up to 12 months
Time to Discontinuation of Vimseltinib
Time frame: Baseline to Discontinuation (Estimated up to 12 months)
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Giant Cell Tumor of Tendon Sheath →
Deciphera Pharmaceuticals, LLC →